Meeting
2021 ASCO Annual Meeting
MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.
Authors
Jose Antonio Lopez Guerrero
Department of Pathology, Medical School, Catholic University of Valencia, Valencia, Spain
Jose Antonio Lopez Guerrero , Carlos Loucera , Marta Ramírez-Calvo , María Peña , Antonio Fernandez-Serra , Angel Guerrero-Zotano , José Palacios , Octavio Burgues , Sonia Servitja , Ignacio Tusquets , Gloria Peiro , Begoña Bermejo , Joan Albanell , Antonio Llombart-Cussac , Joaquin Dopazo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 558)
DOI
10.1200/JCO.2021.39.15_suppl.558
Abstract #
558
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2022 ASCO Annual Meeting
Clinical implications for patients with discordant oncotype and MammaPrint results.
First Author: Matei P. Socoteanu
Poster
2019 ASCO Annual Meeting
Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center.
First Author: Katya Losk
Poster
2018 ASCO Annual Meeting
In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer.
First Author: Hatem Hussein Soliman